X
KEY PRODUCTS
Details:
Through the acquisition, Reddy will leverage the NRT portfolio, which includes Nicotinell (nicotine) in various formats such as lozenges, patches, and gum, across all applicable global market.
Lead Product(s): Nicotine
Therapeutic Area: Psychiatry/Psychology Product Name: Nicotinell
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Haleon
Deal Size: $632.9 million Upfront Cash: $579.8 million
Deal Type: Acquisition June 26, 2024
Details:
Novartis Pharma will be responsible for the supply of Galvus and Galvus Met to DRL. Galvus and Galvus Met are prominent assets in the Dipeptidyl Peptidase-4 (DPP4) inhibitor category.
Lead Product(s): Vildagliptin
Therapeutic Area: Endocrinology Product Name: Galvus
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 27, 2024
Details:
The collaboration aims for commercialization of AVT03 (denosumab), a monoclonal antibody and a biosimilar to Prolia & Xgeva. It is a RANK ligand inhibitor, being evaluated in bone loss in adult men.
Lead Product(s): Denosumab
Therapeutic Area: Musculoskeletal Product Name: AVT03
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Alvotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 21, 2024
Details:
Oracea-Generic (doxycycline) is a tetracycline class drug indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients.
Lead Product(s): Doxycycline
Therapeutic Area: Dermatology Product Name: Oracea-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2024
Details:
Through the agreement, the two companies will establish a joint venture aimed at introducing innovative nutraceutical brands to consumers. The Nestlé Group will license brands like Nature's Bounty (biotin), an approved nutritional supplement for hair, skin, and nails.
Lead Product(s): Biotin,Keratin
Therapeutic Area: Nutrition and Weight Loss Product Name: Nature’s Bounty
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Nestlé India Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 25, 2024
Details:
Loqtorzi (toripalimab-tpzi) is an anti-PD-1 monoclonal antibody, which is an approved product in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma.
Lead Product(s): Toripalimab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Loqtorzi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2024
Details:
Bayer has granted non-exclusive rights to Dr. Reddy’s under the brand name Gantra. Vericiguat, a sGC stimulator, in India, is indicated, along with guideline-based medical therapy, in adults with symptomatic chronic heart failure with reduced ejection fraction.
Lead Product(s): Vericiguat
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Gantra
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Bayer AG
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 05, 2024
Details:
Under the arrangement, Dr. Reddy’s will have exclusive rights to promote and distribute Sanofi’s wellestablished and trusted paediatric and adult vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U.
Lead Product(s): DTaP-IPV-HB-Hib
Therapeutic Area: Infections and Infectious Diseases Product Name: Hexaxim
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 27, 2024
Details:
Under the agreement, Dr. Reddy's has received exclusive rights to market and distribute a first-in-class innovative drug Lyfaquin in India. Developed by Pharmazz, Centhaquine is a resuscitative agent presently indicated for treating hypovolemic shock.
Lead Product(s): Centhaquine
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Lyfaquin
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Pharmazz
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 22, 2024
Details:
Versavo (bevacizumab) is a VEGF A inhibitor indicated for the treatment of cancers including metastatic colorectal cancer, advanced non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma & advanced cervical cancer.
Lead Product(s): Bevacizumab
Therapeutic Area: Oncology Product Name: Versavo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
